Skip to main content
OpenTrials
Completed

NCT Number: NCT00153257

Comparative Study of Mesh Versus No Mesh in Prolapse Surgery

Hypothesis / aims of study A RCT has shown that results of prolapse repair via vaginal approach could be improved when a polypropylene mesh is used as tissue support (1). However, non protected heavy-weight meshes were associated with a high rate of local complications such as vaginal erosions and dyspareunia (2). The aim of this multicentre study is to evaluate anatomical and functional results of an innovative low-weight polypropylene mesh protected by an absorbable hydrophilic film in the prolapse repair by vaginal route, in comparison by the standard anterior colporrhaphy.

Study design, materials and methods This study involves 15 centres in French Private or Public Hospital. Patients will be randomly allocated to be operated by a standard anterior colporrhaphy or by an anterior repair reinforced by a specially designed mesh: UgytexTM (Sofradim, France). Ugytex is a low-weight (38g/m²) and highly porous (average porosity: 89%, pores over 1.5mm) polypropylene monofilament mesh offering tissue ingrowth and connective differentiation for a stable and long-term support. The mesh is coated with a hydrophilic film composed of atelocollagen, polyethylene glycol and glycerol. The absorbable coating protects delicate pelvic viscera from the risk of acute inflammation during the healing's inflammatory peak. Prolapse severity will be evaluated using the POP-Q system. In order to evaluate the patient's quality of life, the validated PFDI and the PFIQ questionnaires will be used preoperatively and during follow-up (3), as well as a validated questionnaire on sexual problems. The difference on one-year cure rate should be 15% (80% for the anterior colporrhaphy and 95% for the mesh repair). Then the estimated number of patient is 97 in each arm.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients older than 60 years-old
  • Anterior vaginal wall prolapse of stage 2 or more (POP-Q system)
  • Symptomatic prolapse
  • Informed consent signature obtained

Exclusion criteria

  • Patient not able to read French language
  • Patient with a anterior prolapse of stage 1
  • Urinary of vaginal infection
  • Hepatopathy with ascitis
  • Diabetes uncontrolled
  • Treatment by corticosteroids
  • Previous pelvic irradiation
  • Intraoperative bladder injury

Treatment and study plan

Ugytex

Device

Anterior repair reinforced by a specially designed mesh: UgytexTM

Primary outcomes

  1. number of anatomical recurrences of anterior vaginal wall prolapse of stage 2 or more (POP-Q system)

    Time frame: 1 year

    POP-Q score

Secondary outcomes

  1. Perioperative and postoperative morbidity

    Time frame: 3 years

    Number of Major and minor complication

  2. Functionnal results following intervention

    Time frame: 3 years

    Symptoms and quality of life questionnaires

  3. Rate of local complications of prosthesis (vaginal erosion, prosthesis shrinkage)

    Time frame: 3 years

  4. Post-operative sexuality

    Time frame: 3 years

    PISQ score

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Nīmes

Other

Collaborators

  • DRRC
  • Medtronic - MITG

Registry information

Official study title

Comparison of the Prosthesis Ugytex by the Trans-obturator Approach and Anterior Colporrhaphy for the Surgical Treatment of Anterior Vaginal Wall Prolapse

Important dates

Study start
2005
Primary completion
2010
Study completion
2013
First posted
Sep 12, 2005
Registry last updated
Nov 21, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.